NVS News and Press, Novartis AG From 02/20/26

2026-02-20 01:34:29 ET More on Novartis Novartis: Value Price, Growth Pipeline Novartis AG 2025 Q4 - Results - Earnings Call Presentation Novartis AG (NVS) Q4 2025 Earnings Call Transcript Novartis inks licensing deal worth up to $1.8B for oral peptide drugs ...

2026-02-19 13:31:04 ET More on AbbVie, AstraZeneca PLC, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable AbbVie: Dominating Immunology While Building Oncology Upside Merck posts n...

2026-02-18 14:13:52 ET More on Pfizer, Johnson & Johnson, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction ...

2026-02-18 13:44:55 ET Since my last article in September, " Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership ," Vertex Pharmaceuticals Incorporated ( VRTX ) stock is up 25.1%.... Read the full article on Seeking Alpha For further detail...

2026-02-18 09:21:20 ET More on Novartis Novartis: Value Price, Growth Pipeline Novartis AG 2025 Q4 - Results - Earnings Call Presentation Novartis AG (NVS) Q4 2025 Earnings Call Transcript Novartis breaks ground on new R&D center in San Diego Nova...

2026-02-17 10:38:59 ET Novartis AG (NYSE: NVS) has caught the attention of the investment community today with its bullish price action. The company’s shares have moved 1.81% on the day to $166.06. Novartis AG researches, develops, manufactures, and markets healthcare product...

2026-02-13 15:07:01 ET It’s been a rough go for Alnylam Pharmaceuticals ( ALNY ) since October 2025, with the shares down almost 40% from an all-time high. While it is typically clinical failures that hit biotechs hard, Alnylam is in that awkward biopharma adolescence where inves...

2026-02-12 16:01:44 ET Strategy GMO International Value ETF ( GMOI ) is an actively managed fund with an objective of total return launched on 10/28/2024. GMOI has a portfolio of 164 stocks, a trailing 12-month yield of 2.44%, and an expense ratio of 0.60%. The fund targets non-...

2026-02-12 14:15:07 ET Deutsche Bank analyst issues BUY recommendation for NVS on February 12, 2026 07:03PM ET. The previous analyst recommendation was Buy. NVS was trading at $161.87 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Curre...

2026-02-11 10:00:00 ET It takes all the running you can do to keep in the same place. If you want to get somewhere else, you must run at least twice as fast! —Through the Looking-Glass (Lewis Carroll) Looking Back About 1.5 years ago, I opened a Long p...